Clinical Trial Update: The Ability Of The PD2i Cardiac Analyzer To Predict Risk Of Ventricular Tachyarrhythmic Events

View source ↗

Summary

This record notes that the clinical trial for the PD2i Cardiac Analyzer to predict ventricular tachyarrhythmic events has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sudden Cardiac Death
• Ventricular Tachycardia

Snippet

Sponsor: Vicor Technologies, Inc. | Conditions: Tachycardia, Ventricular, Cardiac Sudden Death | Status: WITHDRAWN